- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- OncNursingNews.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2023 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Skin Cancers | Clinical
FDA Approval Sought for Cosibelimab as cSCC Treatment
January 05, 2023
Based on findings from a phase 1 study, the FDA has received a biologics license application for cosibelimab for patients with advanced or metastatic cutaneous squamous cell carcinoma.
Roundtable Discussion: Savvides Analyzes Role of Hedgehog Inhibitors and Immunotherapy in BCC
November 29, 2022
During a Targeted Oncology case-based roundtable event, Panayiotis S. Savvides, MD, PhD, MPH, discussed with participants their experiences using hedgehog pathway inhibitors and immunotherapy for patients with basal cell carcinoma.
Potential Impact of Tumor Infiltrating Lymphocytes on Melanoma Treatment
November 20, 2022
Ryan Sullivan, MD, explains how tumor infiltrating lymphocytes could impact the melanoma treatment landscape if approved by the FDA.
Tumor Infiltrating Lymphocyte Data Signal Promise for New Options to Treat Advanced Melanoma
November 16, 2022
In an interview with Targeted Oncology, Ryan J. Sullivan, MD, discussed the history of tumor infiltrating lymphocyte therapy, how new data may lead to approved agents in the future, and other ways tumor infiltrating lymphocytes may be used in advanced melanoma.
Hamid Reviews Options for Patients With Basal Cell Carcinoma and Cutaneous Squamous Cell Carcinoma
November 10, 2022
During a Targeted Oncology case-based roundtable event, Omid Hamid, MD, discussed the data supporting the use of hedgehog pathway inhibitors and immunotherapies for skin cancers.
Significant RFS Benefit Shown With Adjuvant Nivolumab in Stage IIB or IIC Melanoma
October 21, 2022
In patients with completely resected stage IIB or IIC melanoma, use of adjuvant nivolumab achieved a 58% reduction in the risk of recurrence or death.
Bexmarilimab Derives Overall Survival Benefit in PD-1 Blockade Refractory Melanoma
October 19, 2022
Results from the melanoma cohort of the phase 1/2 MATINS show the potential of bexmarilimab monotherapy and combined with other immunotherapies across solid tumors and hematologic malignancies.
Nivolumab Reduces Transformation of Precancerous Leukoplakia to Oral Cancer
October 17, 2022
Glenn J. Hanna, MD, discusses the results of a study investigating nivolumab as treatment for proliferative leukoplakia leading to oral cancer.
Sequential Immunotherapy and Targeted Therapy Shows OS Benefit in BRAF+ Melanoma
October 12, 2022
Three different sequencing schemas for immunotherapy followed by targeted therapy in patients with BRAF V600-mutant melanoma have shown positive survival outcomes and safety consistent with results from prior studies.
IO Before BRAK/MEK Inhibition Is the Ideal Treatment Sequence for BRAF-Mutant Melanoma
October 11, 2022
Data from the DREAMseq trial have answered a lingering question of how to sequence therapy for patients with advanced BRAF-mutant melanoma. This research supports immunotherapy in the first-line setting, followed by BRAK/MEK inhibitors.